Most Shorted Stocks
BEAM is part of our most shorted stocks screen list, indicating it has a high short interest.
BEAM THERAPEUTICS INC (BEAM) Stock Price & Overview
NASDAQ:BEAM • US07373V1052
Current stock price
31.14 USD
-0.05 (-0.16%)
Last:
The current stock price of BEAM is 31.14 USD. Today BEAM is down by -0.16%. In the past month the price increased by 26.63%. In the past year, price increased by 59.78%.
BEAM Key Statistics
52-Week Range15.35 - 36.44
Current BEAM stock price positioned within its 52-week range.
1-Month Range21.63 - 32.48
Current BEAM stock price positioned within its 1-month range.
- Market Cap
- 3.172B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.44
- Dividend Yield
- N/A
BEAM Stock Performance
Today
-0.16%
1 Week
+3.35%
1 Month
+26.63%
3 Months
-1.17%
Longer-term
6 Months +11.55%
1 Year +59.78%
2 Years +46.98%
3 Years +1.56%
5 Years -61.96%
10 Years N/A
BEAM Stock Chart
BEAM Stock Screens
BEAM currently appears in the following ChartMill screener lists.
BEAM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BEAM. When comparing the yearly performance of all stocks, BEAM is one of the better performing stocks in the market, outperforming 82.61% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
BEAM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BEAM. No worries on liquidiy or solvency for BEAM as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BEAM Earnings
On February 24, 2026 BEAM reported an EPS of -0.1 and a revenue of 114.11M. The company beat EPS expectations (89.82% surprise) and beat revenue expectations (790.22% surprise).
Next Earnings DateMay 12, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported-$0.10
Revenue Reported114.109M
EPS Surprise 89.82%
Revenue Surprise 790.22%
BEAM Forecast & Estimates
25 analysts have analysed BEAM and the average price target is 51.08 USD. This implies a price increase of 64.03% is expected in the next year compared to the current price of 31.14.
For the next year, analysts expect an EPS growth of -36.59% and a revenue growth 23.86% for BEAM
Analysts
Analysts86.4
Price Target51.08 (64.03%)
EPS Next Y-36.59%
Revenue Next Year23.86%
BEAM Groups
Sector & Classification
BEAM Financial Highlights
Over the last trailing twelve months BEAM reported a non-GAAP Earnings per Share(EPS) of -3.44. The EPS increased by 24.83% compared to the year before.
Income Statements
Revenue(TTM)139.74M
Net Income(TTM)-79.99M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.4% | ||
| ROE | -6.46% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%90.55%
Sales Q2Q%279.52%
EPS 1Y (TTM)24.83%
Revenue 1Y (TTM)120.01%
BEAM Ownership
Ownership
Inst Owners104.69%
Shares101.86M
Float100.45M
Ins Owners1.36%
Short Float %23.27%
Short Ratio12.05
BEAM Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.76 | 360.314B | ||
| AMGN | AMGEN INC | 15.34 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.4 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.83 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.02 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.6 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.42 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BEAM
Company Profile
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 511 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Company Info
IPO: 2020-02-06
BEAM THERAPEUTICS INC
238 Main Street
Cambridge MASSACHUSETTS 02139 US
CEO: John Evans
Employees: 511
Phone: 13026587581
BEAM THERAPEUTICS INC / BEAM FAQ
What does BEAM THERAPEUTICS INC do?
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 511 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Can you provide the latest stock price for BEAM THERAPEUTICS INC?
The current stock price of BEAM is 31.14 USD. The price decreased by -0.16% in the last trading session.
Does BEAM stock pay dividends?
BEAM does not pay a dividend.
What is the ChartMill rating of BEAM THERAPEUTICS INC stock?
BEAM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does BEAM THERAPEUTICS INC belong to?
BEAM THERAPEUTICS INC (BEAM) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for BEAM THERAPEUTICS INC?
The Revenue of BEAM THERAPEUTICS INC (BEAM) is expected to grow by 23.86% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.